Skip to main content

NRX Pharmaceuticals, Inc 10-Q for FY2026 Q3

NRX Pharmaceuticals, Inc. (NRXP)

10-Q 2026-11-16 For: 2026-09-30
View Original
Added on November 17, 2026

About this 10-Q

NRX Pharmaceuticals, Inc filed this 10-Q on November 16, 2026, covering the quarter ended September 30, 2026 (FY2026 Q3).

NRx reported a $20.1 million net loss for the nine months ended September 30, 2026, and management concluded substantial doubt exists about its ability to continue as a going concern. AI summary

Headline figures

Quarter ended September 30, 2026, as reported in this filing, compared with the same period a year earlier where the filing states it.

Revenue
$1.16M
up 378.9% from $242K a year earlier
Net loss
$2.18M
compared with a net loss of $5.89M a year earlier